Table 4.
Study | Disease or diagnosis | Age (years) | Ethnicity or cultural identity | Description of illness severity acuity/frailty (from text) | Highest level of engagement | Research activities where patients provided input (from text) | Stages of the research cycle | |||
---|---|---|---|---|---|---|---|---|---|---|
Foundation | Preparation | Execution | Translation | |||||||
Absolom 2015 [45] | Heterogeneous cancers - including gastro-intestinal, breast, prostate, and gynecological | 50–70 yrs | n/r | Patients on active treatment for cancer. | Collaborate | Grant writing; proposal development; research design; recruitment strategy development; tool refinement; implementation & dissemination. 2 patients on the steering committee (SC) which oversaw and advised the study. | √ | √ | √ | |
Arain 2015 [46] |
Heterogeneous cancers | n/r | “diversity” | Patients on treatment for cancer type; including colorectal, breast, lung, brain and prostate. | Collaborate | Grant writing; proposal development; research design; tool refinement (patient information sheets for clinical trials, questionnaires); advice for increasing trial recruitment, conducting patient interviews. Patients also sat on project team. | √ | √ | √ | |
Bates 2018 [47] |
Heterogeneous cancers | n/r | n/r | Patients receiving palliative care for advanced cancer. | Collaborate | Engaged in data collection and data analysis, dissemination activities. | √ | √ | √ | |
Bethell 2018 [48] | Dementia | n/r | n/r | Different types/stages of dementia – varying degrees of cognitive impairment. | Collaborate | Identification and prioritization of research questions. 1 person with dementia included on the steering committee which oversaw and advised the study. Persons with dementia were involved in: promoting surveys and recruitment. | √ | √ | √ | |
Bethell 2019 [49] | Older Adults with Frailty | n/r | n/r | Those with lived experience of frailty. | Collaborate | Identification of research priorities. People with lived experience of frailty included on steering committee which oversaw and advised the study. | √ | √ | √ | |
Burns 2018 [50] |
Hematological malignancies | n/r | n/r | Patients who have undergone hematopoietic cell transplant. | Collaborate | Identified research priorities. Provided advice on patient engagement. Patients also participated on SC and working groups throughout the entire research cycle (details and outcomes of contribution provided). | √ | √ | √ | √ |
Caldon 2010 [51] | Breast cancer | n/r | n/r | Patients with cancer. One patient partner died prior to publication of the study. | Collaborate | Co-development of the project – tools, documentation, and processes. Also involved in dissemination and co-authorship. | √ | √ | √ | |
Chiu 2013 [7] |
Breast cancer | n/r | n/r | Some participants on active treatment. | Collaborate | Provided input through all phases of the research from grant development to dissemination of study findings. Other activities included refinement of research questions, survey development, data analysis, presentations, and co-authorship. | √ | √ | √ | |
Collins 2015 [24] | Heterogeneous cancers & palliative | 22–75 | n/r | Level of acuity not documented in cancer patients but includes palliative patients | Collaborate | Co-researchers across different projects from influencing the research agenda through to dissemination as co-authors and presenters at conferences. | √ | √ | √ | |
Corner 2007 [52] | Heterogeneous cancers (including breast, gastrointestinal, lung, hematological, etc.) & palliative | 30–70 | n/r |
16% on active treatment; 13% receiving palliative care. Inclusion of other stakeholders, e.g., caregivers, ex-patients (cancer survivors). Patients were excluded if deemed by clinical team to be too unwell, have complicating health factors or liable to be distressed by participating. |
Collaborate | Identification of research priorities. The co-researchers ‘co-owned’ the study with the unit, and as such had a direct influence on all aspects of the study, including data collection, analysis and dissemination of study findings. | √ | √ | √ | √ |
Cotterell 2011 [53] | Heterogeneous cancers, COPD, Stills Disease, Parkinson’s Disease | 41–78 | “diversity” |
Patients receiving active treatment and patients receiving palliative care (for non-malignancies). Inclusion of other stakeholders, e.g., caregivers, ex-patients (cancer survivors) |
Collaborate | Involved as integral members of the research team throughout the length of the study; data collection, analysis and dissemination of study findings. | √ | √ | √ | |
Davis 2019 [54] |
Frail older adults | n/r | Pakistani, Somalian, Yemeni | Frail older adults. | Collaborate | Identification of research topics. Provided advice on methods of patient engagement to develop sustainable infrastructure. Developed a PPI structure. Patients/caregivers included on steering committee. | √ | √ | √ | |
Froggatt 2015 [55] | Heterogeneous cancers | 51–84 | n/r | Patients experiencing recurrence of disease and those receiving ongoing treatment | Collaborate | Research partners across different studies in cancer research collaborative. Provided input regarding barriers to patient engagement. The term research partner was proposed by the co-applicant patient representative on the management group as reflecting the nature of the PPI working that was to be developed in the collaborative | √ | √ | √ | |
Heaven 2016 [56] | Frailty | 75+ | n/r | Older adults with frailty. | Collaborate | Engaged throughout a number of studies from grant writing/proposal development, research conduct, dissemination. Participation on research steering/advisory committees. | √ | √ | √ | |
Iwata 2019 [57] |
Head and neck cancers | 35–74 | 10% Asian, Hispanic or Latino |
Included patients on active treatment. Inclusion of other stakeholders, e.g., caregivers, ex-patients (cancer survivors). |
Collaborate | Engaged in identification of research priorities, hypothesis generation, feedback on tools and processes, clinical flow and dissemination. | √ | √ | √ | √ |
Jones 2017 [58] |
Kidney cancer | n/r | n/r | Included patients on current active treatment and those awaiting surgical treatment. | Collaborate | Identifying and prioritizing research questions. 7 Patients/caregivers included on steering committee; contributed throughout study design and execution; defining the scope of the partnership, development of the protocol, identifying potential partners and stakeholders, and oversight of the process. | √ | √ | √ | |
Jorgensen 2018 [59] |
Heterogeneous cancers | n/r | n/r |
Included patients on active treatment. Inclusion of other stakeholders, e.g., a caregiver, ex-patients (cancer survivors). |
Collaborate | Engaged throughout research cycle: co-application on grants, literature review participation, outcome and tool development, feedback on the conduct of the research, presentations, co-authorship. | √ | √ | √ | |
Jorgensen 2018 [60] |
Heterogeneous cancers | n/r | n/r |
Included peer interviewer with advanced age and stage of illness. Co-researchers also included caregivers, ex-patients (cancer survivors). |
Collaborate | Involved in study design, conduct of research (conducting peer interviews), data analysis. | √ | √ | ||
Lechelt 2018 [61] | Head and neck cancers | n/r | n/r |
Broad spectrum of patients, varying tumor types and sites, including newly diagnosed, those on current active treatment. Inclusion of other stakeholders, e.g., caregivers, ex-patients (cancer survivors). |
Collaborate | Identification of research priorities. 5 patients on the steering committee which established consensus on desired scope and inclusion/exclusion criteria for the project regarding: respondent groups, question categories; tumor types/site; developed the survey; oversaw all aspects of the project. | √ | √ | √ | |
Litherland 2018 [62] | Dementia | n/r | n/r | Different types/stages of dementia – varying degrees of cognitive impairment. | Collaborate | Engaged in shaping project materials, providing feedback on questionnaires and interview processes, reviewing emerging theoretical themes, and presenting project findings. | √ | √ | √ | |
Littlechild 2015 [63] | Dementia | n/r | “diversity” | Older persons with varying types/stages of dementia – varying degrees of cognitive impairment. | Collaborate | Engaged at all stages of the study, including: designing the research method and tools, identifying key themes and findings at the analysis stage, dissemination activities. | √ | √ | √ | |
Parveen 2018 [64] | Dementia | n/r | n/r | Different types/stages of dementia – varying degrees of cognitive impairment | Collaborate | Engaged in discussing study progress, findings and interpretation of data | √ | √ | √ | |
Perkins 2008 [65] | Heterogeneous cancers | 65 median | n/r | Included palliative patients with a prognosis of 6 months or less. | Involve | Patient input into identification of research domains, piloting of questionnaires prior to prioritization of research questions. | a | √ | √ | |
Piil 2019 [66] |
Primary malignant brain tumor and acute leukemia | 22–59 | n/r | Life threatening cancer diagnosis, characterized by poor and uncertain prognosis, undergoing aggressive and intensive oncological treatments resulting in a complex symptom burden. | Collaborate | Identifying and prioritizing research questions. Patients included on steering committee and contributed throughout study design & execution; defining scope of the partnership, development of the protocol, identifying potential partners and stakeholders, and oversight of the process. Additional details included in published study protocol [73]. | √ | √ | √ | √ |
Schölvinck 2019 [67] | Hematological malignancies | 19–75+ | n/r | Patients from all disease phases and types. | Collaborate | Identification and prioritization of research questions and outcomes. Patient representatives included on the research steering/advisory committee. | √ | √ | √ | |
Stephens 2015 [68] | Mesothelioma | n/r | n/r | Patients with high symptom burden. | Collaborate | Identification and prioritization of research questions. Patients sat on the research advisory committee which oversaw and advised the study. . | √ | √ | √ | |
Stevenson 2019 [69] | Dementia | < 65–75+ | n/r | Cognitive impairment - early to mid-stage dementia. | Involve | Engaged in deriving meaning from the data, identifying and connecting themes. | √ | |||
Tanner 2012 [70] |
Dementia | 60–77 | n/r | Cognitive impairment – progressive during the study. | Involve | Engaged as co-researchers involved in conducting interviews. | √ | |||
Wright 2006 [71] |
Heterogeneous cancers | n/r | n/r |
Includes patients undergoing treatment. Inclusion of other stakeholders, e.g., caregivers, ex-patients (cancer survivors). |
Involve | Engaged in the design and conduct of the study (including co-facilitation of focus groups). Also engaged in subsequent data analysis and dissemination activities. | √ | √ | √ | |
Wright 2006 [72] |
Disease/s not specified (palliative) | n/r | n/r | Patients receiving palliative care. | Collaborate | Engaged in the design and conduct of the study. Co-research role throughout the course of the study. | √ | √ | √ | |
Totals: n (%) |
13 43% |
28 93% |
30 100% |
18 60% |
n/r not reported
aResearch prioritization reported in prior publication [74]